Tag Archives: Collateral

AAA Marketing–Don’t Assume Your Customer is Stupid [unGPP Case Study]

Author:

At least once a week, and sometimes daily, I run across the undoubtedly well-intended efforts of marketing people who need an education in transparency, how their product is used and who their target market is. This is the first in a series of unGPP, where I will present and dissect these real-life examples. Many will be outside the highly regulated sphere of pharma and medical devices as these may be good, non-threatening examples for internal discussion. Continue reading

70% of Medical Companies Need Social Media Procedures

Author:

In December, Deloitte reported that 65% of Life Sciences company professionals use or plan to use social networking.  While the top-line statistics garnered a lot of attention, the following paragraph caught my eye:

Despite the potential risks that could be associated with online social networking, half (50 percent) of surveyed respondents who report they are responsible for managing risk related to online social networks, say their companies do not have a formal risk policy in place and 43 percent do not have procedures for managing adverse events [for social media].Continue reading

Promotional Content Team? 52% of Companies Do.

Author:

In a recent poll during a RAPS webinar, 52% of medical device, biotech and pharma companies had a cross-functional promotional review team who met regularly.  This is a great start.  Continue reading

Be Prepared

Author: Stacey Homan


It was almost five years ago, but I remember it like it was yesterday.

Whispers started going around the office…”the FDA is here”.  I had just joined the marketing department for a medical device company a short time earlier and we were about to undergo an audit of our marketing materials and procedures.

A month before we had undergone a complete overhaul of our procedures, but would it hold? We were still making small tweaks to the system and now it was going to undergo an intense two-week audit where everything was on the line.  As a start-up you are not afforded many mistakes. Continue reading